Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Outsmart™ IL-2/15, a Novel Cytokine Designed to Enhance ROR1-Specific CAR T Anti-Tumor Activity While Minimizing Treg Activation and Systemic Cytokine Exposure

Howell Moffett, Brian Weitzner, Thaddeus Davenport, Leah Tait, Tina Tan, Laura Baker, John Crowl, Willimark Obenza, Bradley Hammerson, Robin Kirkpatrick, Paul Sample, Lesley Jones, Erik Hermans, Robert Langan, Kevin Haworth, Scott Boyken, Aaron Foster, Marc Lajoie

Blood (2023) 142 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2023-182417

Published: 2023

Journal Articles

Development of a Regulated, Optimized Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Mesothelin Positive Cancers

Blood (2023) 142 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2023-190321

Published: 2023

Journal Articles

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Jeremy M. Kinder, Chanel Athena-Estrada, Danyal Malik, Xiaomeng Hu, Meghan Lamba, Chi Young, Neal Van Hoeven, Brian Granger, Vandana Chaturvedi, Ouwen Liang, Jesus Moreno, Aaron Lampano, Garrett Zipp, Adam Johnson, Terry Fry, Sonja Schrepfer, Aaron Foster

Blood (2022) 140 (Supplement 1): 7120–7121.

https://doi.org/10.1182/blood-2022-166845

Published: 2022

Journal Articles

Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells

Darin Salloum, PhD, Kavita Tundwal, Divy Kangeyan, PhD, Adam Johnson, Neal van Hoeven, PhD, Brian Granger, Jesus Moreno, Ouwen Liang, Pascal Beauchesne, Terry J. Fry, Aaron Foster

Blood (2022) 140 (Supplement 1): 4524–4525.

https://doi.org/10.1182/blood-2022-168372

Published: 2022

Journal Articles

A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape

Adam Johnson, Hallee Wright, Xiaomeng Hu, Neal van Hoeven, PhD, Brian Granger, Ouwen Liang, Jesus Moreno, Meghan Lamba, Chi Young, Andrew McAlister, Terry J. Fry, Sonja Schrepfer, Aaron Foster

Blood (2022) 140 (Supplement 1): 4552–4553.

https://doi.org/10.1182/blood-2022-168251

Published: 2022

Journal Articles

Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

Xiaomeng Hu, Pascal Beauchesne, Karl Manner, Corie Gattis, Priscilla Ngo, Rowena De Jesus, Chi Young, Frank Wells, Lindong Weng, Kathy White, William E Dowdle, Aaron Foster, Terry Fry, Sonja Schrepfer

Blood (2022) 140 (Supplement 1): 1173–1175.

https://doi.org/10.1182/blood-2022-167943

Published: 2022

Journal Articles

CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

Jesse Green, Adam Johnson, Brian Granger, Ouwen Liang, Jesus Moreno, Andrew Tucker, Hallee Wright, Brian Dolinski, Hanane Ennajdaoui, Semih Tareen, Neal van Hoeven, PhD, Jagesh Shah, Kutlu Elpek, Aaron Foster, Terry J. Fry

Blood (2022) 140 (Supplement 1): 7768–7769.

https://doi.org/10.1182/blood-2022-162705

Published: 2022

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40

Xiaomei Wang, PhD, Wei-Chun Chang, PhD, Daniel L. Jasinski, PhD, Jan L. Medina, BS, Ming Zhang, BS, Aaron Foster, PhD, David M. Spencer, PhD, J. Henri Bayle, PhD

Blood (2018) 132 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2018-99-120151

Published: 2018

Journal Articles

A Simplified Method for Transduction and Expansion of T Cells for Clinical Application

Mariam Khalil, Aaron Foster, PhD, Christine Gagliardi, PhD

Blood (2018) 132 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2018-99-119254

Published: 2018

Journal Articles

T- and B-Cell Neogenesis Recovers Efficiently in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Followed By Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 cells)

Marialuigia Catanoso, MD, Emmanuel Clave, PhD, Corinne Douay, Mattia Algeri, MD, Isabelle Fournier, Valentina Bertaina, Itaua Leston Araujo, MSc, Francesca Del Bufalo, MD, Federica Galaverna, MD, Cecilia Surace, PhD, Alice Bertaina, MD PhD, Pietro Merli, MD, Aaron Foster, PhD, Antoine Toubert, MD PhD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 4560.

https://doi.org/10.1182/blood-2018-99-116536

Published: 2018

Journal Articles

Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies

Joanne Shaw, PhD, Xiaoou Zhou, MD PhD, An Lu, Valentina Bertaina, Daria Pagliara, MD PhD, Melissa Aldinger, PharmD, David M. Spencer, PhD, Franco Locatelli, Aaron Foster, PhD

Blood (2018) 132 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2018-99-119779

Published: 2018

Journal Articles

Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion

Xiaoou Zhou, MD PhD, An Lu, Kelly L Sharp, Margie Harris, Madhavi Anumula, MS, J. Bayle, PhD, David M. Spencer, PhD, Aaron Foster, PhD, Joanne Shaw, PhD

Blood (2018) 132 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2018-99-119285

Published: 2018

Journal Articles

Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post-Allograft Infusion in Patients Given αβ T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (αβ haplo-HSCT) Contributing to Accelerate Immune Recovery

Pietro Merli, MD, Valentina Bertaina, Federica Galaverna, MD, Mattia Algeri, MD, Matilde Sinibaldi, Luisa Strocchio, Giuseppina Li Pira, Daria Pagliara, Sonia De Murtas, Giuseppe Palumbo, Vincent O'Neill, David M. Spencer, Aaron Foster, Alice Bertaina, MD PhD, Franco Locatelli, MD PhD

Blood (2017) 130 (Supplement 1): 211.

https://doi.org/10.1182/blood.V130.Suppl_1.211.211

Published: 2017

Journal Articles

Single-Cell Multiplex Proteomics Reveals Synergistic Impact of Antigen and Rimiducid-Dependent Stimulatory Signals on Promoting Polyfunctional GoCAR-T Cells Targeting Prostate Stem Cell Antigen (PSCA)

Sean Mackay, Brianna Flynn, Kevin Morse, Colin Ng, Kyle Gallatin, Patrick Paczkowski, Aruna Mahendravada, Nicholas Shinners, David M. Spencer, Aaron Foster, Jing Zhou

Blood (2017) 130 (Supplement 1): 2281.

https://doi.org/10.1182/blood.V130.Suppl_1.2281.2281

Published: 2017

Journal Articles

MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9

Aaron Foster, Pei-Yi Lin, PhD, An Lu, Wei-Chun Chang, PhD, Nicholas Shinners, Mariam Khalil, Jeannette Crisostomo, Aruna Mahendravada, Kevin M. Slawin, MD, David M. Spencer

Blood (2017) 130 (Supplement 1): 4615.

https://doi.org/10.1182/blood.V130.Suppl_1.4615.4615

Published: 2017

Journal Articles

Inducible MyD88/CD40 (iMC) Costimulation Enhances Polyclonal Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte (EBV-CTL) Proliferation and Anti-Tumor Activity

Mariam Khalil, Eric Yvon, S., Aruna Mahendravada, David M. Spencer, Aaron Foster

Blood (2017) 130 (Supplement 1): 3337.

https://doi.org/10.1182/blood.V130.Suppl_1.3337.3337

Published: 2017

Journal Articles

Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123 + Cancer

J. Henri Bayle, PhD, MyLinh T Duong, PhD, An Lu, Eva Morschl, PhD, Matthew R. Collinson-Pautz, PhD, Kelly L Sharp, Slawomir Szymanski, PhD, Mary E. Brandt, Kevin M. Slawin, MD, Steven Toler, PhD, Eric Yvon, S., Aaron Foster, David M. Spencer

Blood (2017) 130 (Supplement 1): 3184.

https://doi.org/10.1182/blood.V130.Suppl_1.3184.3184

Published: 2017

Journal Articles

Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9

Aaron Foster, PhD, Peter Chang, PhD, Pei-Yi Lin, PhD, Jeannette Crisostomo, Aruna Mahendravada, An Lu, Mariam Khalil, Sunandan Saha, PhD, Joanne Shaw, PhD, Eva Morschl, PhD, Kevin M Slawin, MD, David M Spencer, PhD

Blood (2015) 126 (23): 851.

https://doi.org/10.1182/blood.V126.23.851.851

Published: 2015

Journal Articles

Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells

Aaron Foster, PhD, Aruna Mahendravada, Nicholas P Shinners, PhD, Peter Chang, PhD, An Lu, Eva Morschl, PhD, Joanne Shaw, PhD, Sunandan Saha, PhD, Kevin M Slawin, MD, David M Spencer, PhD

Blood (2015) 126 (23): 4295.

https://doi.org/10.1182/blood.V126.23.4295.4295

Published: 2015

NARROW

Outsmart™ IL-2/15, a Novel Cytokine Designed to Enhance ROR1-Specific CAR T Anti-Tumor Activity While Minimizing Treg Activation and Systemic Cytokine Exposure

Development of a Regulated, Optimized Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Mesothelin Positive Cancers

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells

A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape

Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Regulated Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40

A Simplified Method for Transduction and Expansion of T Cells for Clinical Application

T- and B-Cell Neogenesis Recovers Efficiently in Children with Acute Leukemia Given an Alpha-Beta T-Cell Depleted Haplo-HSCT Followed By Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 cells)

Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies

Differential Expression of Inducible Caspase-9 (iC9) in Allogeneic T Cells Allows Selective Depletion of Activated T Cells Following Exposure to Rimiducid and Permits In Vivo Allodepletion

Single-Cell Multiplex Proteomics Reveals Synergistic Impact of Antigen and Rimiducid-Dependent Stimulatory Signals on Promoting Polyfunctional GoCAR-T Cells Targeting Prostate Stem Cell Antigen (PSCA)

MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9

Inducible MyD88/CD40 (iMC) Costimulation Enhances Polyclonal Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte (EBV-CTL) Proliferation and Anti-Tumor Activity

Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123 + Cancer

Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9

Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only